Response of HIV RNA to didanosine as a predictive marker of survival

AIDS

Volumn 9, Issue 2, 1995, Pages 159-163

  Yerly, Sabine ^a   Kaiser, Laurent ^a   Mermillod, Bernadette ^a   Baumberger, Christophe ^a   Hirschel, Bernard ^a   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

AIDS; Didanosine; Drug resistance; HIV; Prognostic marker; Viraemia

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; VIRUS RNA;

AIDS RELATED COMPLEX; ARTICLE; CLINICAL ARTICLE; DEATH; DRUG RESISTANCE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; STATISTICS; SURVIVAL; VIREMIA;

EID: 0028878787     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199502000-00007     Document Type: Article

References (14)

1. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987, 317:185-191.
2. Kahn JO, Lagakos SW, Richman DD, et al.: A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992, 327:581-587.
3. Concorde Coordinating Committee: MRC/ARNS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
4. Coombs RW, Collier AC, Allain JP, et al.: Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989, 321:1626-1631.
5. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC: Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994, 169:416-419.
6. Molina J-M, Ferchal F, Chevret S, et al.: Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. AIDS 1994, 8:27-33.
7. Richman DD, Grimes J, Lagakos SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990, 3: 743-746.
8. St Clair MH, Martin JL, Tudor Williams G, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
9. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
10. Darbyshire JH, Aboulker J-P: Didanosine for zidovudine-intolerant patients with HIV-disease. Lancet 1992, 340:1346-1347.
11. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
12. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin L: Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr (in press).
13. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5:137-144.
14. McLeod G, McGrath JM, Ladd EA, Hammer S: Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother 1992, 36:920-925.